AI Article Synopsis
- Tirzepatide is the first dual incretin receptor activator approved for treating type II diabetes and obesity.
- It has shown benefits in reducing liver fat without known cases of liver damage from its use.
- However, a case of elevated liver enzymes was reported in a 37-year-old woman with metabolic syndrome after using tirzepatide.
Article Abstract
Tirzepatide is the first dual incretin glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor activator approved for the management of type II diabetes mellitus. This drug was also recently approved by the Food and Drug Administration as a management option for patients with obesity. Tirzepatide has been also reported to be beneficial in reducing liver fat content. Although its efficacy is well described in the literature, no cases of tirzepatide-induced hepatotoxicity have been reported. We report a case of a 37-year-old woman with metabolic syndrome who was noted to have elevated liver enzymes secondary to tirzepatide use.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452087 | PMC |
| http://dx.doi.org/10.14309/crj.0000000000001484 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Rare Case of Tirzepatide-Induced Hepatotoxicity.
ACG Case Rep J
October 2024
Department of Hepatology, Liver Institute Northwest, Seattle, WA.
Article Synopsis
- Tirzepatide is the first dual incretin receptor activator approved for treating type II diabetes and obesity.
- It has shown benefits in reducing liver fat without known cases of liver damage from its use.
- However, a case of elevated liver enzymes was reported in a 37-year-old woman with metabolic syndrome after using tirzepatide.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!